Elicio Therapeutics, Inc. (ELTX) Stock

Elicio Therapeutics, Inc. (ELTX) is a Healthcare stock trading at $3.66 (as of 2026-06-18), with a market capitalization of $218.34M and a trailing P/E of -1.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing a pipeline of immunotherapies aimed at cancer and other diseases. Its programs include therapeutic and adjuvant vaccine candidates (such as ELI-002 and related agents), additional AMP-peptide vaccines for specific cancer mutations, and a T cell AMP-lifier approach for mKRAS-driven cancers.

Valuation — source: SEC EDGAR (first-party)
Price	$3.66
Market Cap	$218.34M
P/E Ratio	-1.6
EV / EBITDA	-1.8
Price / Book	-51.14
Price / Sales	468.03
DCF Value (model)	$-33.12
DCF Upside vs Price	-1004.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.30M
Net Margin	-1686.5%
Return on Equity	2796.5%
Debt / Equity	-6.59
Current Ratio	2.24
Revenue Growth (YoY)	7.6%
EPS Growth (YoY)	-56.8%
FCF Growth (YoY)	6.3%

Valuation vs Sector & Industry
Stock P/E	-1.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-107.8%
vs Industry	-109.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Knoll Capital Management, LLC ($6.74M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Robert T. Connelly
Employees	32
Country	US
IPO Date	2021-02-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.